Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting
Rapport Therapeutics (NASDAQ: RAPP) announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (December 6-10, 2024, Los Angeles). The company will present new data on the correlation between long episode frequency reduction and clinically meaningful reduction in patient-reported seizures, derived from an RNS® System study.
The presentations include data from their Phase 2a trial of RAP-219, their lead product candidate for drug-resistant focal epilepsy. Four poster presentations will cover antiseizure effects, pharmacokinetics, safety, and tolerability studies. A Scientific Exhibit Room session will showcase these posters along with additional information about RAP-219's development and trial design.
Rapport Therapeutics (NASDAQ: RAPP) ha annunciato diverse presentazioni al prossimo American Epilepsy Society Annual Meeting (6-10 dicembre 2024, Los Angeles). L'azienda presenterà nuovi dati sulla correlazione tra la riduzione della frequenza degli episodi prolungati e una riduzione clinicamente significativa delle crisi segnalate dai pazienti, derivati da uno studio sul sistema RNS®.
Le presentazioni includeranno dati dal loro trial di fase 2a di RAP-219, il loro principale candidato terapeutico per l'epilessia focale resistente ai farmaci. Quattro presentazioni poster tratteranno gli effetti antiepilettici, la farmacocinetica, la sicurezza e gli studi di tollerabilità. Una sessione nella Sala Espositiva Scientifica presenterà questi poster insieme ad ulteriori informazioni sullo sviluppo di RAP-219 e sul design del trial.
Rapport Therapeutics (NASDAQ: RAPP) anunció múltiples presentaciones en la próxima Reunión Anual de la Sociedad Americana de Epilepsia (6-10 de diciembre de 2024, Los Ángeles). La empresa presentará nuevos datos sobre la correlación entre la reducción de la frecuencia de episodios prolongados y una reducción clínicamente significativa en las convulsiones reportadas por los pacientes, derivados de un estudio del sistema RNS®.
Las presentaciones incluirán datos de su ensayo de fase 2a de RAP-219, su principal candidato a medicamento para la epilepsia focal resistente a tratamientos. Cuatro presentaciones en cartel cubrirán los efectos anticonvulsivos, la farmacocinética, la seguridad y los estudios de tolerabilidad. Una sesión en la Sala de Exposición Científica mostrará estos carteles junto con información adicional sobre el desarrollo y el diseño del ensayo de RAP-219.
Rapport Therapeutics (NASDAQ: RAPP)는 다가오는 미국 간질학회 연례 회의 (2024년 12월 6-10일, 로스앤젤레스)에서 여러 발표를 할 것이라고 발표했습니다. 이 회사는 RNS® 시스템 연구에서 도출된 환자가 보고한 발작의 임상적으로 유의미한 감소와 장기 에피소드 빈도 감소 사이의 상관관계에 대한 새로운 데이터를 발표할 것입니다.
발표에는 약물 내성 국소 간질을 위한 주요 후보 제품인 RAP-219의 2a상 임상 시험의 데이터가 포함됩니다. 네 개의 포스터 발표는 항발작 효과, 약리학적 동태, 안전성 및 내약성 연구를 다룹니다. 과학 전시실 세션에서는 RAP-219의 개발 및 연구 설계에 대한 추가 정보와 함께 이러한 포스터를 선보일 것입니다.
Rapport Therapeutics (NASDAQ: RAPP) a annoncé plusieurs présentations lors de la prochaine Réunion Annuelle de la Société Américaine d'Épilepsie (6-10 décembre 2024, Los Angeles). L'entreprise présentera de nouvelles données sur la corrélation entre la réduction de la fréquence des épisodes prolongés et une réduction cliniquement significative des crises rapportées par les patients, issues d'une étude sur le système RNS®.
Les présentations incluront des données de leur essai de phase 2a de RAP-219, leur principal candidat thérapeutique pour l'épilepsie focale résistante aux médicaments. Quatre présentations sous forme de posters porteront sur les effets anti-crise, la pharmacocinétique, la sécurité et les études de tolérance. Une session dans la Salle d'Exposition Scientifique mettra en avant ces posters ainsi que des informations supplémentaires sur le développement et le design de l'essai de RAP-219.
Rapport Therapeutics (NASDAQ: RAPP) hat mehrere Präsentationen auf dem bevorstehenden Jahrestreffen der American Epilepsy Society (6.-10. Dezember 2024, Los Angeles) angekündigt. Das Unternehmen wird neue Daten zur Korrelation zwischen der Reduzierung der Häufigkeit längerer Episoden und einer klinisch relevanten Reduzierung der von den Patienten berichteten Anfälle präsentieren, die aus einer Studie mit dem RNS®-System stammen.
Die Präsentationen beinhalten Daten aus ihrer Phase 2a-Studie zu RAP-219, ihrem Hauptkandidaten für die medikamentenresistente fokale Epilepsie. Vier Posterpräsentationen decken die anti-eplileptischen Wirkungen, Pharmakokinetik, Sicherheit und Verträglichkeit ab. Eine Sitzung im wissenschaftlichen Ausstellungsraum wird diese Poster zusammen mit weiteren Informationen zur Entwicklung und Studiengestaltung von RAP-219 präsentieren.
- None.
- None.
Poster presentations on Phase 2a trial seizure biomarker, preclinical, and Phase 1 clinical data
BOSTON and SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting, taking place December 6-10, 2024, in Los Angeles.
Using analysis from an open-label, long-term treatment study of the RNS® System, Rapport will present key new data on the correlation between the reduction in long episode (LE) frequency (abnormal electrographic activity) and clinically meaningful reduction (
The full schedule of Rapport posters at AES is as follows:
| Date & Location | Poster Title | Presenter |
| Saturday, Dec. 07, 2024, 12:00 – 6:00 p.m. PST South Hall H, Level 1 | Antiseizure Effects with Selective TARPγ8 Negative Allosteric Modulators in Preclinical Seizure Models (Poster #390) | Jose Matta, PhD; Brock Shireman, PhD; Laurie Volak, PhD; Michael Maher, PhD; David Bredt, MD, PhD |
| Saturday, Dec. 07, 2024, 12:00 – 6:00 p.m. PST South Hall H, Level 1 | Impact of Food on the PK and Tolerability of RAP-219 in Healthy Volunteers (Poster #409) | Stephen Greene, PharmD; Swamy Yeleswaram, PhD |
| Saturday, Dec. 07, 2024, 12:00 – 6:00 p.m. PST South Hall H, Level 1 | Optimal Cut Point for Reduction in Long Episode Frequency to Predict Meaningful Change in Clinical Seizure Frequency (Poster #494) | Arnold R Gammaitoni, PharmD, Martha J. Morrell, MD, Jacqueline A French, MD, Daniel Friedman, MD, Kathryn A Davis, MD, Thomas K Tcheng, PhD, Cairn Seale, MS, Bradley S Galer, MD, William W Motley, MD |
| Sunday, Dec. 08, 2024, 10:00 – 4:00 p.m. PST South Hall H, Level 1 | Safety, Tolerability, and Pharmacokinetics of RAP-219 in Healthy Volunteers (Poster #372) | Swamy Yeleswaram, PhD; Bradley Galer, MD; William Motley, MD; Stephen Greene, PharmD |
Our Scientific Exhibit Room will take place on Monday, Dec. 09, 2024, 2:00 – 5:00 p.m. PST in room 406AB. We will be showcasing:
1) All of the above posters
2) Evolution of RAP-219 for the Treatment of Epilepsy
3) Novel Design of a Focal Epilepsy Proof-of-Concept Study of RAP-219, a Negative Allosteric Modulator of the γ8 Transmembrane AMPA Receptor-Associated Regulatory Protein (TARPγ8)
Following the conference, Rapport’s presentations will be available within the Publications section of the company’s website.
For more information on the AES Annual Meeting, please visit: https://aesnet.org/AES-annual-meeting.
About RAP-219
RAP-219 is a clinical-stage AMPAR (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) negative allosteric modulator (NAM) designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPγ8, which is associated with the neuronal AMPAR. Whereas AMPARs are distributed widely in the central nervous system (CNS), TARPγ8 is expressed only in discrete regions, including the hippocampus and cortex. Because of this restricted expression of TARPγ8 in forebrain regions, the Company believes RAP-219 has the potential to provide a differentiated clinical profile, including improved activity and tolerability along with a higher therapeutic index, potentially providing more patients with sustained therapeutic benefit without intolerable side effects, as compared to traditional neuroscience medications. Due to the role of AMPA biology in various neurological disorders and the precision approach of selective targeting of TARPγ8, the Company believes RAP-219 has significant pipeline-in-a-product potential and is currently evaluating the compound as a transformational treatment for patients with focal epilepsy, peripheral neuropathic pain, and bipolar disorder.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients suffering from central nervous system (CNS) disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead clinical program, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently advancing RAP-219 in clinical trials in focal epilepsy, peripheral neuropathic pain, and bipolar disorder. Additional preclinical and late-stage discovery stage programs are also underway, targeting CNS disorders including chronic pain and hearing disorders.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the expected impact of reductions in long episode frequency as measured by the RNS® System; the clinical development of RAP-219 for the treatment of drug-resistant focal epilepsy, peripheral neuropathic pain and bipolar disorder; the potential activity and tolerability of RAP-219; and the potential of Rapport’s RAP technology platform.
Forward looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect Rapport’s business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the company’s research and development activities; Rapport’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; Rapport’s ability to attract, integrate and retain key personnel; risks related to the company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining Rapport’s intellectual property protections; and risks related to the competitive landscape for Rapport’s product candidates; as well as other risks described in “Risk Factors,” in the company’s Registration Statement on Form S-1, and most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Rapport’s subsequent filings with the Securities and Exchange Commission. Rapport expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
FAQ
What will Rapport Therapeutics (RAPP) present at the 2024 American Epilepsy Society Meeting?
What is the main focus of Rapport Therapeutics' (RAPP) Phase 2a trial presented at AES 2024?
When and where will Rapport Therapeutics (RAPP) present their Scientific Exhibit at AES 2024?
